Mednax Stock Price, News & Analysis (NYSE:MD)

$51.58 -0.10 (-0.19 %)
(As of 12/14/2017 09:55 AM ET)
Previous Close$51.68
Today's Range$51.23 - $51.96
52-Week Range$40.56 - $72.13
Volume1.15 million shs
Average Volume1.09 million shs
Market Capitalization$4.84 billion
P/E Ratio15.8
Dividend YieldN/A
Beta0.4

About Mednax (NYSE:MD)

Mednax logoMEDNAX, Inc. is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company's national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. As of December 31, 2016, the Company had over 1,390 affiliated physicians providing anesthesia care to patients in connection with surgical and other procedures, as well as pain management. As of December 31, 2016, the Company had 270 affiliated physicians providing maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.

Receive MD News and Ratings via Email

Sign-up to receive the latest news and ratings for MD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Healthcare Facilities & Services
Sub-IndustryHealth Care Services
SectorMedical
SymbolNYSE:MD
CUSIP58502B10
Phone954-384-0175

Debt

Debt-to-Equity Ratio0.62%
Current Ratio1.37%
Quick Ratio1.37%

Price-To-Earnings

Trailing P/E Ratio15.8
Forward P/E Ratio16.64
P/E Growth1.67

Sales & Book Value

Annual Sales$3.18 billion
Price / Sales1.52
Cash Flow$4.83 per share
Price / Cash10.69
Book Value$29.48 per share
Price / Book1.75

Profitability

Trailing EPS$2.83
Net Income$324.91 million
Net Margins7.76%
Return on Equity10.80%
Return on Assets5.57%

Miscellaneous

Employees7,400
Outstanding Shares93,650,000

Mednax (NYSE:MD) Frequently Asked Questions

What is Mednax's stock symbol?

Mednax trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

How were Mednax's earnings last quarter?

Mednax, Inc (NYSE:MD) posted its quarterly earnings data on Wednesday, November, 1st. The company reported $0.87 earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of $0.87. The company earned $868.95 million during the quarter, compared to analysts' expectations of $864.78 million. Mednax had a net margin of 7.76% and a return on equity of 10.80%. Mednax's revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.09 earnings per share. View Mednax's Earnings History.

When will Mednax make its next earnings announcement?

Mednax is scheduled to release their next quarterly earnings announcement on Monday, February, 5th 2018. View Earnings Estimates for Mednax.

What guidance has Mednax issued on next quarter's earnings?

Mednax updated its fourth quarter earnings guidance on Wednesday, November, 1st. The company provided earnings per share guidance of $0.80-0.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.85.

Where is Mednax's stock going? Where will Mednax's stock price be in 2017?

11 Wall Street analysts have issued 12 month target prices for Mednax's shares. Their predictions range from $44.00 to $69.00. On average, they expect Mednax's stock price to reach $53.70 in the next twelve months. View Analyst Ratings for Mednax.

What are Wall Street analysts saying about Mednax stock?

Here are some recent quotes from research analysts about Mednax stock:

  • 1. According to Zacks Investment Research, "Mednax, Inc., formerly Pediatrix Medical Group, Inc. is a healthcare services company that focuses on physician services for newborn, maternal-fetal, pediatric subspecialty and anesthesia care. The company ,through its subsidiaries, provides these services in the United States and Puerto Rico. In addition, MEDNAX engages in clinical research, monitoring clinical outcomes, and implementing clinical initiatives. " (10/11/2017)
  • 2. Jefferies Group LLC analysts commented, "Following MD's 5% EPS miss in Q4, we believe our Hold thesis from our December downgrade still holds and would expect the stock to give up some of its premium valuation pending improved earnings visibility. Broader birth trends remain subdued, MD faces its toughest comp of the year in Q1-17, and the company's deal flow remains relatively moderate, leading us to believe that the achievability of Q1 guidance (following 3 consecutive EPS misses) remains uncertain." (2/8/2017)

Who are some of Mednax's key competitors?

Who are Mednax's key executives?

Mednax's management team includes the folowing people:

  • Cesar L. Alvarez, Chairman of the Board (Age 69)
  • Joseph M. Calabro, President, Chief Operating Officer (Age 56)
  • Roger J. Medel M.D., Chief Executive Officer, Director (Age 70)
  • Vivian Lopez-Blanco, Chief Financial Officer, Treasurer (Age 59)
  • David A. Clark, President - MEDNAX National Medical Group Division (Age 50)
  • John C. Pepia, Senior Vice President, Chief Accounting Officer (Age 54)
  • Dominic J. Andreano, Senior Vice President, General Counsel, Secretary (Age 48)
  • Manuel Kadre, Lead Independent Director (Age 51)
  • Karey D. Barker, Independent Director (Age 49)
  • Waldemar A. Carlo M.D., Independent Director (Age 64)

Who owns Mednax stock?

Mednax's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Thompson Siegel & Walmsley LLC (2.78%), Longview Partners Guernsey LTD (2.66%), Nordea Investment Management AB (2.48%), Wedge Capital Management L L P NC (2.25%), ELLIOTT ASSOCIATES, L.P. (2.00%) and Earnest Partners LLC (1.60%). Company insiders that own Mednax stock include Cesar L Alvarez, Dominic J Andreano, Enrique Sosa, John C Pepia, Joseph M Calabro, Karl B Wagner, Manuel Kadre, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Michael D Stanley, Paul G Gabos, Robert Irwin Valliant and Vivian Lopez-Blanco. View Institutional Ownership Trends for Mednax.

Who sold Mednax stock? Who is selling Mednax stock?

Mednax's stock was sold by a variety of institutional investors in the last quarter, including Longview Partners Guernsey LTD, Wasatch Advisors Inc., Sterling Capital Management LLC, Ameriprise Financial Inc., Macquarie Group Ltd., TD Asset Management Inc., Bank of New York Mellon Corp and SG Americas Securities LLC. Company insiders that have sold Mednax company stock in the last year include Cesar L Alvarez, Dominic J Andreano, Enrique Sosa, John C Pepia, Joseph M Calabro, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Paul G Gabos, Robert Irwin Valliant and Vivian Lopez-Blanco. View Insider Buying and Selling for Mednax.

Who bought Mednax stock? Who is buying Mednax stock?

Mednax's stock was purchased by a variety of institutional investors in the last quarter, including Toronto Dominion Bank, JPMorgan Chase & Co., Prudential Financial Inc., Thompson Siegel & Walmsley LLC, Dimensional Fund Advisors LP, MUFG Securities EMEA plc, Caisse DE Depot ET Placement DU Quebec and BNP Paribas Arbitrage SA. Company insiders that have bought Mednax stock in the last two years include Manuel Kadre and Md Pascal J Goldschmidt. View Insider Buying and Selling for Mednax.

How do I buy Mednax stock?

Shares of Mednax can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mednax's stock price today?

One share of Mednax stock can currently be purchased for approximately $51.58.

How big of a company is Mednax?

Mednax has a market capitalization of $4.84 billion and generates $3.18 billion in revenue each year. The company earns $324.91 million in net income (profit) each year or $2.83 on an earnings per share basis. Mednax employs 7,400 workers across the globe.

How can I contact Mednax?

Mednax's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at 954-384-0175 or via email at [email protected]


MarketBeat Community Rating for Mednax (MD)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  245 (Vote Outperform)
Underperform Votes:  278 (Vote Underperform)
Total Votes:  523
MarketBeat's community ratings are surveys of what our community members think about Mednax and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Mednax (NYSE:MD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.152.082.002.00
Ratings Breakdown: 1 Sell Rating(s)
9 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $54.82$54.50$59.25$66.56
Price Target Upside: 6.07% upside25.66% upside34.38% upside21.25% upside

Mednax (NYSE:MD) Consensus Price Target History

Price Target History for Mednax (NYSE:MD)

Mednax (NYSE:MD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/13/2017Piper Jaffray CompaniesInitiated CoverageOverweight -> Overweight$58.00LowView Rating Details
11/3/2017CitigroupLower Price TargetNeutral$52.00 -> $47.00N/AView Rating Details
11/3/2017Robert W. BairdBoost Price TargetNeutral$47.00 -> $48.00N/AView Rating Details
11/3/2017Jefferies GroupReiterated RatingHold$44.00N/AView Rating Details
11/1/2017KeyCorpSet Price TargetBuy$51.00N/AView Rating Details
10/16/2017BMO Capital MarketsInitiated CoverageMarket Perform$46.00N/AView Rating Details
8/1/2017MizuhoReiterated RatingNeutral$62.00 -> $48.00MediumView Rating Details
6/22/2017StephensUpgradeEqual Weight -> Overweight$55.00 -> $68.00HighView Rating Details
5/25/2017Stifel NicolausLower Price TargetHold$65.00 -> $58.00LowView Rating Details
5/4/2017Bank of AmericaDowngradeBuy -> UnderperformLowView Rating Details
3/10/2017J P Morgan Chase & CoReiterated RatingOverweight -> Neutral$69.00LowView Rating Details
12/9/2016Goldman Sachs GroupInitiated CoverageNeutral$66.00N/AView Rating Details
10/27/2016Raymond James FinancialDowngradeOutperform -> Market PerformN/AView Rating Details
3/7/2016Susquehanna BancsharesDowngradePositive -> Neutral$94.00 -> $70.00N/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

Mednax (NYSE:MD) Earnings History and Estimates Chart

Earnings by Quarter for Mednax (NYSE:MD)

Mednax (NYSE MD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/5/2018N/AView Earnings Details
11/1/2017Q3 2017$0.87$0.87$864.78 million$868.95 millionViewN/AView Earnings Details
7/28/2017Q2 2017$0.81$0.85$849.49 million$843.00 millionViewN/AView Earnings Details
5/4/2017Q1 2017$0.74$0.75$837.01 million$835.60 millionViewN/AView Earnings Details
2/7/2017Q416$1.06$1.00$842.15 million$831.00 millionViewListenView Earnings Details
10/27/2016Q316$1.05$1.09$821.18 million$828.00 millionViewListenView Earnings Details
7/28/2016Q216$1.07$1.03$775.68 million$772.00 millionViewListenView Earnings Details
4/28/2016Q116$0.86$0.87$741.49 million$752.60 millionViewListenView Earnings Details
2/4/2016Q415$1.10$1.13$748.02 million$742.00 millionViewListenView Earnings Details
10/29/2015Q315$0.97$1.10$730.63 million$722.30 millionViewListenView Earnings Details
7/30/2015Q215$0.88$0.97$677.02 million$676.60 millionViewListenView Earnings Details
4/30/2015Q115$0.71$0.72$641.24 million$639.40 millionViewListenView Earnings Details
1/29/2015Q414$0.87$0.89$637.90 million$651.00 millionViewListenView Earnings Details
10/30/2014Q314$0.85$0.86$619.61 million$627.00 millionViewListenView Earnings Details
7/31/2014Q214$0.78$0.79$603.00 million$595.54 millionViewListenView Earnings Details
5/1/2014Q114$0.63$0.63$574.80 million$566.00 millionViewListenView Earnings Details
1/30/2014Q4$0.75$0.20$555.30 million$567.00 millionViewListenView Earnings Details
10/31/2013Q313$1.48$1.52$556.63 million$555.00 millionViewListenView Earnings Details
7/30/2013Q2 2013$1.36$1.37$533.39 million$529.18 millionViewListenView Earnings Details
5/2/2013Q1 2013$1.09$1.10$504.24 million$502.70 millionViewListenView Earnings Details
1/31/2013Q4 2012$1.30$1.32$473.70 million$471.30 millionViewListenView Earnings Details
11/1/2012Q312$1.28$1.32$470.60 million$473.10 millionViewN/AView Earnings Details
7/31/2012$1.19$1.22ViewN/AView Earnings Details
5/3/2012$1.00$0.98ViewN/AView Earnings Details
2/2/2012$1.19$1.19ViewN/AView Earnings Details
11/1/2011$1.18$1.19ViewN/AView Earnings Details
8/2/2011$1.15$1.15ViewN/AView Earnings Details
5/3/2011$0.91$0.94ViewN/AView Earnings Details
2/3/2011$1.12$1.12ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Mednax (NYSE:MD) Earnings Estimates

2017 EPS Consensus Estimate: $3.58
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.80$0.81$0.81
Q2 20172$0.99$1.00$1.00
Q3 20173$0.77$1.07$0.88
Q4 20173$0.79$1.09$0.90
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Mednax (NYSE:MD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Mednax (NYSE MD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.40%
Institutional Ownership Percentage: 98.48%
Insider Trades by Quarter for Mednax (NYSE:MD)
Institutional Ownership by Quarter for Mednax (NYSE:MD)

Mednax (NYSE MD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/12/2017John C PepiaInsiderSell3,000$51.58$154,740.00View SEC Filing  
11/3/2017Cesar L AlvarezDirectorSell10,668$42.59$454,350.12View SEC Filing  
9/12/2017John C PepiaInsiderSell3,000$42.85$128,550.00View SEC Filing  
6/14/2017Md Pascal J GoldschmidtDirectorSell1,969$57.57$113,355.33View SEC Filing  
6/1/2017Joseph M CalabroInsiderSell23,327$55.00$1,282,985.00View SEC Filing  
5/5/2017Manuel KadreDirectorBuy21,704$55.79$1,210,866.16View SEC Filing  
5/5/2017Vivian Lopez-BlancoCFOSell7,778$55.82$434,167.96View SEC Filing  
3/16/2017Robert Irwin ValliantDirectorSell5,200$1.10$5,720.00
2/23/2017Enrique SosaDirectorSell10,668$69.65$743,026.20View SEC Filing  
2/17/2017Vivian Lopez-BlancoCFOSell15,164$70.01$1,061,631.64View SEC Filing  
2/16/2017Dominic J AndreanoSVPSell6,000$69.59$417,540.00View SEC Filing  
2/16/2017John C PepiaInsiderSell2,500$69.58$173,950.00View SEC Filing  
2/16/2017Paul G GabosDirectorSell21,336$69.63$1,485,625.68View SEC Filing  
2/10/2017Md Pascal J GoldschmidtDirectorSell25,294$67.82$1,715,439.08View SEC Filing  
2/9/2017Md Carlo A WaldemarDirectorSell5,334$67.90$362,178.60View SEC Filing  
1/17/2017Vivian Lopez-BlancoCFOSell10,000$70.95$709,500.00View SEC Filing  
12/7/2016Md Pascal J GoldschmidtDirectorBuy2,100$66.52$139,692.00View SEC Filing  
9/14/2016Md Pascal J GoldschmidtDirectorSell1,500$65.01$97,515.00View SEC Filing  
6/13/2016Dominic J AndreanoSVPSell3,922$68.80$269,833.60View SEC Filing  
6/8/2016Md Carlo A WaldemarDirectorSell5,334$70.50$376,047.00View SEC Filing  
6/7/2016Karl B WagnerInsiderSell27,482$68.45$1,881,142.90View SEC Filing  
6/1/2016Joseph M CalabroCOOSell28,347$67.78$1,921,359.66View SEC Filing  
6/1/2016Michael D StanleyInsiderSell14,778$67.78$1,001,652.84View SEC Filing  
5/16/2016Dominic J AndreanoSVPSell3,000$68.53$205,590.00View SEC Filing  
5/2/2016Vivian Lopez-BlancoCFOSell9,350$71.22$665,907.00View SEC Filing  
3/11/2016Md Pascal J GoldschmidtDirectorSell3,100$65.00$201,500.00View SEC Filing  
2/29/2016Paul G GabosDirectorSell10,668$67.15$716,356.20View SEC Filing  
12/11/2015Md Pascal J. GoldschmidtDirectorSell5,250$70.99$372,697.50View SEC Filing  
9/8/2015Cesar L. AlvarezDirectorSell10,668$81.00$864,108.00View SEC Filing  
8/27/2015Roger Md MedelCEOSell100,000$80.27$8,027,000.00View SEC Filing  
6/8/2015Karl B WagnerInsiderSell37,820$70.28$2,657,989.60View SEC Filing  
6/3/2015Joseph M CalabroCOOSell108,071$70.51$7,620,086.21View SEC Filing  
3/9/2015Md Pascal J GoldschmidtDirectorSell8,500$71.25$605,625.00View SEC Filing  
2/26/2015Roger Md MedelCEOSell100,000$71.61$7,161,000.00View SEC Filing  
2/20/2015Md Carlo A WaldemarDirectorSell10,668$71.50$762,762.00View SEC Filing  
2/6/2015Dominic J AndreanoSVPSell3,200$70.75$226,400.00View SEC Filing  
2/6/2015Vivian Lopez-BlancoCFOSell8,250$69.95$577,087.50View SEC Filing  
2/2/2015Paul G GabosDirectorSell17,584$68.07$1,196,942.88View SEC Filing  
1/30/2015William C HawkCOOSell3,598$68.50$246,463.00View SEC Filing  
11/14/2014Roger Md MedelCEOSell51,290$62.59$3,210,241.10View SEC Filing  
11/13/2014Roger Md MedelCEOSell63,440$62.55$3,968,172.00View SEC Filing  
11/7/2014Roger Md MedelCEOSell128,833$62.60$8,064,945.80View SEC Filing  
11/5/2014Roger Md MedelCEOSell169,845$62.60$10,632,297.00View SEC Filing  
11/4/2014Roger Md MedelCEOSell15,052$62.52$941,051.04View SEC Filing  
11/3/2014Roger Md MedelCEOSell10,881$62.52$680,280.12View SEC Filing  
10/31/2014Roger Md MedelCEOSell61,592$62.58$3,854,427.36View SEC Filing  
10/30/2014Karl B WagnerInsiderSell40,000$62.50$2,500,000.00View SEC Filing  
10/30/2014Vivian Lopez-BlancoCFOSell8,800$60.00$528,000.00View SEC Filing  
7/30/2014Karl B WagnerInsiderSell80,000$60.00$4,800,000.00View SEC Filing  
6/10/2014Dominic J AndreanoSVPSell2,252$58.48$131,696.96View SEC Filing  
6/6/2014Karl B WagnerInsiderSell44,596$58.53$2,610,203.88View SEC Filing  
6/5/2014William C HawkCOOSell6,911$57.66$398,488.26View SEC Filing  
6/2/2014David A ClarkCOOSell16,230$57.00$925,110.00View SEC Filing  
6/2/2014Michael D StanleyInsiderSell18,006$57.00$1,026,342.00View SEC Filing  
5/9/2014Karl WagnerInsiderSell79,524$57.09$4,540,025.16View SEC Filing  
5/9/2014Md Pascal GoldschmidtDirectorSell30,000$57.11$1,713,300.00View SEC Filing  
5/8/2014Joseph CalabroCOOSell137,500$57.06$7,845,750.00View SEC Filing  
2/20/2014Dominic AndreanoSVPSell3,000$61.00$183,000.00View SEC Filing  
2/10/2014Joseph CalabroCOOSell150,000$55.55$8,332,500.00View SEC Filing  
2/10/2014Md Carlo WaldemarDirectorSell10,668$55.40$591,007.20View SEC Filing  
11/7/2013Enrique SosaDirectorSell5,334$107.00$570,738.00View SEC Filing  
11/7/2013Karl WagnerInsiderSell1,800$107.60$193,680.00View SEC Filing  
9/11/2013William C HawkCOOSell3,162$100.62$318,160.44View SEC Filing  
9/10/2013Dominic J AndreanoSVPSell3,718$99.63$370,424.34View SEC Filing  
8/7/2013Karl WagnerInsiderSell25,000$98.01$2,450,250.00View SEC Filing  
8/2/2013Joseph M CalabroCOOSell36,154$98.57$3,563,699.78View SEC Filing  
6/3/2013David A ClarkCOOSell8,645$91.01$786,781.45View SEC Filing  
6/3/2013Michael D StanleyInsiderSell8,906$91.01$810,535.06View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Mednax (NYSE MD) News Headlines

Source:
DateHeadline
Mednax (MD) Coverage Initiated by Analysts at Piper Jaffray CompaniesMednax (MD) Coverage Initiated by Analysts at Piper Jaffray Companies
www.americanbankingnews.com - December 13 at 11:10 PM
The Latest Wall Street Recommendations for MednaxThe Latest Wall Street Recommendations for Mednax
finance.yahoo.com - December 13 at 5:26 PM
Mednax, Inc (MD) Insider John C. Pepia Sells 3,000 SharesMednax, Inc (MD) Insider John C. Pepia Sells 3,000 Shares
www.americanbankingnews.com - December 12 at 6:06 PM
Traders Buy Large Volume of Mednax Put Options (MD)Traders Buy Large Volume of Mednax Put Options (MD)
www.americanbankingnews.com - December 4 at 2:26 AM
Mednax volatile amidst rumored takeover interestMednax volatile amidst rumored takeover interest
seekingalpha.com - December 1 at 7:21 PM
Mednax, Inc (MD) Expected to Post Quarterly Sales of $886.36 MillionMednax, Inc (MD) Expected to Post Quarterly Sales of $886.36 Million
www.americanbankingnews.com - December 1 at 6:04 PM
Mednax fielding takeover interest from buyout firms -sourcesMednax fielding takeover interest from buyout firms -sources
finance.yahoo.com - December 1 at 4:54 PM
 Brokerages Anticipate Mednax, Inc (MD) Will Post Earnings of $0.83 Per Share Brokerages Anticipate Mednax, Inc (MD) Will Post Earnings of $0.83 Per Share
www.americanbankingnews.com - November 29 at 3:26 AM
MEDNAX to Present at Upcoming Investor ConferencesMEDNAX to Present at Upcoming Investor Conferences
finance.yahoo.com - November 23 at 6:22 AM
MEDNAX Radiology to Exhibit at RSNA 2017 Annual Meeting Nov. 26-30MEDNAX Radiology to Exhibit at RSNA 2017 Annual Meeting Nov. 26-30
finance.yahoo.com - November 22 at 3:17 AM
Contrasting Quest Diagnostics (DGX) and Mednax (MD)Contrasting Quest Diagnostics (DGX) and Mednax (MD)
www.americanbankingnews.com - November 19 at 3:28 PM
Mednax, Inc (MD) Receives Average Recommendation of "Hold" from BrokeragesMednax, Inc (MD) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 19 at 11:54 AM
Paul Singer's hedge fund just bought a big chunk of this small health-care companyPaul Singer's hedge fund just bought a big chunk of this small health-care company
finance.yahoo.com - November 17 at 8:33 PM
A Big Hedge Fund Is Behind Mednax Soaring 12.7% TodayA Big Hedge Fund Is Behind Mednax Soaring 12.7% Today
finance.yahoo.com - November 17 at 8:33 PM
Mednax Inc. (MD) Surged On News Of Elliott Management StakeMednax Inc. (MD) Surged On News Of Elliott Management Stake
www.rttnews.com - November 17 at 3:29 PM
MEDNAX, Inc.: Price momentum supported by strong fundamentalsMEDNAX, Inc.: Price momentum supported by strong fundamentals
finance.yahoo.com - November 17 at 3:29 PM
Hedge fund led by ‘World’s Most Feared Investor’ buys stake in South Florida companyHedge fund led by ‘World’s Most Feared Investor’ buys stake in South Florida company
finance.yahoo.com - November 17 at 3:29 PM
Paul Singers hedge fund just bought a big chunk of this small health-care companyPaul Singer's hedge fund just bought a big chunk of this small health-care company
www.cnbc.com - November 16 at 3:28 PM
 Analysts Expect Mednax, Inc (MD) Will Announce Quarterly Sales of $886.36 Million Analysts Expect Mednax, Inc (MD) Will Announce Quarterly Sales of $886.36 Million
www.americanbankingnews.com - November 15 at 12:06 PM
ETFs with exposure to MEDNAX, Inc. : November 14, 2017ETFs with exposure to MEDNAX, Inc. : November 14, 2017
finance.yahoo.com - November 15 at 6:17 AM
Zacks: Brokerages Expect Mednax, Inc (MD) Will Announce Earnings of $0.83 Per ShareZacks: Brokerages Expect Mednax, Inc (MD) Will Announce Earnings of $0.83 Per Share
www.americanbankingnews.com - November 13 at 5:38 AM
Comparing Midland Exploration (MD) & Its PeersComparing Midland Exploration (MD) & Its Peers
www.americanbankingnews.com - November 12 at 7:12 PM
$886.36 Million in Sales Expected for Midland Exploration Inc. (MD) This Quarter$886.36 Million in Sales Expected for Midland Exploration Inc. (MD) This Quarter
www.americanbankingnews.com - November 12 at 9:30 AM
HealthStream (HSTM) versus Mednax (MD) Financial ComparisonHealthStream (HSTM) versus Mednax (MD) Financial Comparison
www.americanbankingnews.com - November 10 at 5:24 AM
MEDNAX to Present at the Stifel 2017 Healthcare ConferenceMEDNAX to Present at the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 8 at 5:38 PM
Jefferies Group LLC Reiterates "Hold" Rating for Mednax, Inc (MD)Jefferies Group LLC Reiterates "Hold" Rating for Mednax, Inc (MD)
www.americanbankingnews.com - November 5 at 5:40 PM
Mednax, Inc (MD) Given New $48.00 Price Target at Robert W. BairdMednax, Inc (MD) Given New $48.00 Price Target at Robert W. Baird
www.americanbankingnews.com - November 5 at 10:06 AM
MEDNAX, Inc. :MD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 2, 2017MEDNAX, Inc. :MD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 2, 2017
finance.yahoo.com - November 3 at 10:53 PM
Mednax, Inc (MD) Price Target Cut to $47.00Mednax, Inc (MD) Price Target Cut to $47.00
www.americanbankingnews.com - November 3 at 9:20 PM
Cesar L. Alvarez Sells 10,668 Shares of Mednax, Inc (MD) StockCesar L. Alvarez Sells 10,668 Shares of Mednax, Inc (MD) Stock
www.americanbankingnews.com - November 3 at 5:42 PM
BRIEF-Mednax reports Q3 earnings per share of $0.71BRIEF-Mednax reports Q3 earnings per share of $0.71
www.businessinsider.com - November 3 at 4:58 PM
ETFs with exposure to MEDNAX, Inc. : November 3, 2017ETFs with exposure to MEDNAX, Inc. : November 3, 2017
finance.yahoo.com - November 3 at 4:58 PM
Mednax, Inc (MD) Announces Quarterly  Earnings ResultsMednax, Inc (MD) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 2 at 7:32 PM
MEDNAX (MD) Q3 2017 Results - Earnings Call TranscriptMEDNAX (MD) Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 2 at 6:15 AM
Mednax tops Street 3Q forecastsMednax tops Street 3Q forecasts
finance.yahoo.com - November 2 at 6:15 AM
With A Recent ROE Of 10.86%, Can MEDNAX Inc (MD) Catch Up To Its Industry?With A Recent ROE Of 10.86%, Can MEDNAX Inc (MD) Catch Up To Its Industry?
finance.yahoo.com - November 2 at 6:15 AM
Edited Transcript of MD earnings conference call or presentation 1-Nov-17 2:00pm GMTEdited Transcript of MD earnings conference call or presentation 1-Nov-17 2:00pm GMT
finance.yahoo.com - November 2 at 6:15 AM
KeyCorp Analysts Give Mednax, Inc (MD) a $51.00 Price TargetKeyCorp Analysts Give Mednax, Inc (MD) a $51.00 Price Target
www.americanbankingnews.com - November 1 at 1:22 PM
Mednax, Inc (MD) Releases Q4 Earnings GuidanceMednax, Inc (MD) Releases Q4 Earnings Guidance
www.americanbankingnews.com - November 1 at 10:54 AM
MEDNAX, Inc. breached its 50 day moving average in a Bearish Manner : MD-US : October 31, 2017MEDNAX, Inc. breached its 50 day moving average in a Bearish Manner : MD-US : October 31, 2017
finance.yahoo.com - November 1 at 6:08 AM
MEDNAX Reports Third Quarter GAAP EPS of $0.71; Adjusted EPS of $0.87MEDNAX Reports Third Quarter GAAP EPS of $0.71; Adjusted EPS of $0.87
finance.yahoo.com - November 1 at 6:08 AM
Why Mednax (MD) Might Surprise This Earnings Season?Why Mednax (MD) Might Surprise This Earnings Season?
finance.yahoo.com - October 31 at 3:39 AM
Reviewing Mednax (MD) and HealthStream (HSTM)Reviewing Mednax (MD) and HealthStream (HSTM)
www.americanbankingnews.com - October 28 at 5:30 PM
Mednax, Inc (MD) Given Consensus Rating of "Hold" by AnalystsMednax, Inc (MD) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - October 25 at 3:38 PM
$867.22 Million in Sales Expected for Mednax, Inc (MD) This Quarter$867.22 Million in Sales Expected for Mednax, Inc (MD) This Quarter
www.americanbankingnews.com - October 23 at 2:54 AM
Head-To-Head Comparison: Mednax (MD) vs. Its CompetitorsHead-To-Head Comparison: Mednax (MD) vs. Its Competitors
www.americanbankingnews.com - October 23 at 2:08 AM
$0.84 EPS Expected for MEDNAX Inc (MD) This Quarter$0.84 EPS Expected for MEDNAX Inc (MD) This Quarter
www.americanbankingnews.com - October 21 at 8:28 PM
MEDNAX’s American Anesthesiology to Exhibit at the ANESTHESIOLOGY® 2017 Annual Meeting Oct. 21-23MEDNAX’s American Anesthesiology to Exhibit at the ANESTHESIOLOGY® 2017 Annual Meeting Oct. 21-23
finance.yahoo.com - October 21 at 6:24 AM
Corporate News Blog - MEDNAX Acquires Synergy Radiology AssociatesCorporate News Blog - MEDNAX Acquires Synergy Radiology Associates
finance.yahoo.com - October 21 at 6:24 AM
MEDNAX, Inc. breached its 50 day moving average in a Bullish Manner : MD-US : October 20, 2017MEDNAX, Inc. breached its 50 day moving average in a Bullish Manner : MD-US : October 20, 2017
finance.yahoo.com - October 21 at 6:24 AM

SEC Filings

Mednax (NYSE:MD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Mednax (NYSE:MD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Mednax (NYSE MD) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.